Obesity: lack of reimbursement limits market potential

Published By Datamonitor

Inflammatory bowel disease: new treatments won't set market alight

Inflammatory bowel disease (IBD), primarily constituted of ulcerative colitis and Crohn's disease, affects approximately 1.8 million people in the seven major markets. Datamonitor forecasts a growing market and the launch of six major brands in IBD indications in as many years. However, few appear to offer especially novel mechanisms of action.

Published By Datamonitor

Rise of the superbug set to drive antibacterials growth

The increasing incidence of multi-resistant superbugs is emerging as a major global health concern. Although there are several candidates for the treatment of methicillin-resistant Staphylococcus aureus other pathogens such Pseudomonas aeruginosa or Acinetobacter Baumannii pose an even larger threat. This largely unmet urgent need for treatments should drive growth in the antibacterials market.

Published By Datamonitor

HIV market: collaborative combinations

Two new HIV drugs, from Tibotec and Gilead, have been shown to be viable late-stage pipeline candidates. However, both TMC278 and elvitegravir are set to compete head-to-head against more widely-used competitors. In the longer term, both candidates could improve usage and penetration through use in collaborative combination therapies.

Published By Datamonitor

Cervical cancer: vaccines set to drastically reduce incidence

Despite a significant drop in the incidence of cervical cancer in the western world due to routine screening, cervical cancer remains the second most common cancer in women the world over. However, two new vaccines for the human papilloma virus (HPV), a major risk factor for cervical cancer, are set to have a dramatic impact on the incidence of cervical cancer all over the globe.

Published By Datamonitor

Lung cancer market: opportunities exist for targeting rarer tumor types

Published By Datamonitor

Migraine market: Trexima approval delays benefits generic triptan

Estimated to be worth $3.4 billion in 2005, the migraine market is entering a state of maturity driven by the dominance of the triptan class of drugs. The ongoing approval delays with GlaxoSmithKline and Pozen's Trexima, coupled with triptan genericization, will result in the migraine market value decreasing by 20% from 2008 to $3.2 billion in 2015.

Published By Datamonitor

Major depressive disorder: potential high sales for GSK's pipeline drug

Published By Datamonitor

Hospital acquired infections: crucial need for gram-negative antibacterials

Published By Datamonitor

Changing of the guard in HIV treatment

The HIV market is forecast to grow from $7.1 billion in 2005 to an estimated $10.6 billion in 2015. This growth is to be driven by a combination of several factors, including an increase in the number of people diagnosed, and the launch of several new drugs and drug classes which offer new hope to patients who otherwise would have at-best limited, but perhaps no therapeutic options left at all.

Published By Datamonitor